Just like Hurricane Harvey, COVID-19 is causing Houstonians to rethink how they operate — and that tech and innovation inversion is opening the door to new opportunities. Photo via Getty Images

For has long as I can remember, I had to live near water. That's why I moved to Houston. Recently, new neighbors moved next door from the downtown Galleria area. They loved it there until coronavirus turned shopping habits into stay-at-home habits. The experience led them to recognize they could do just fine without the Galleria-area routine, pivoting instead to a maritime lifestyle.

Could COVID-19 be triggering an inversion paradigm? An inversion paradigm puts needs first rather than product first. We have experienced many historic technology inversions. Remember when our televisions were air-wave dependent and telephones were tethered to the wall? Because the need evolved for a phone that was mobile, today our TV's are wired, and our telephones are untethered.

This technology inversion fundamentally found its way to the individual consumer and transformed entire industries. Houston businesses are responding to a rare COVID-19-induced disruption. Inversions are rare, but when they occur, opportunity follows.

Large infrastructure challenges are normally led by bureaucratic funding processes that result in productized solutions. Hurricane Harvey was a wake-up call to take decisive action to protect decades of private and public investment against future flood events. It was an analogue to removing the board with the nail in it from the driveway to avoid endless tire repairs.

Now, Houston's resilience infrastructure is going through a Hurricane Harvey-induced inversion. The fundamental approach to water management is experiencing a historic reversal which focuses on need rather than a response cycle. Largely dependent on surface run-off systems, Houston experienced a river running through it during Hurricane Harvey. In response, studies and projects are underway to consider a major underground storm drainage system. Water management is fundamentally changing to move stormwater from above ground to below grade, while domestic water is moving away from underground sources to surface supplies, such as lakes. These programs reduce threats to downtown, allowing urbanism and businesses to flourish, simply by addressing a human need in lieu of building another drainage product.

Fortunately for the Houston economy, pre-COVID, quasi-inversion programs already in place to address mobility needs, such as the $7.5 billion METRONext program and $4.8 billion for flood control essentials, are injecting billions of dollars into the local economy. At the federal level, future stimulus funding designed to address infrastructure needs and the economic impact of Coronavirus are likely to follow next year. Consequently, the current Hurricane Harvey, COVID-19 inversion could position Houston to rebound from a time of trial reimagining what a next generation city in the modern age should look like.

Graphic courtesy of AECOM

In fact, infrastructure programs have a long history of creating sustainable jobs and transforming cities. Did you know the River Walk in San Antonio, a downtown centerpiece that thrives today and contributes to thousands of job opportunities, was a construction project born during the Great Depression to address a disastrous flood occurring in the early 1920s? San Antonio architect Robert H. H. Hugman was elected to address a need to save lives and reimagine San Antonio's downtown. The city was altered forever by creating a flood resilience infrastructure that also transformed its city center into a civic gathering place that made San Antonio one of the largest destination cities in Texas.

While technology inversions are occurring more often than before, they are still rare, and each one is very important. Infrastructure inversions that transform cites are even more exceptional. In a COVID-19-induced inversion period, the possibilities are limitless, and the time is now. With programs underway and potential stimulus funding to support additional investment to address city needs, Houston is positioned for something amazing.

------

Tony Loyd is based in Houston and vice president at AECOM.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston digital health platform Koda lands strategic investment

money moves

Houston-based advance care planning platform Koda Health has added another investor to the lineup.

The company secured a strategic investment for an undisclosed amount from UPMC Enterprises, the commercialization arm of the University of Pittsburgh Medical Center. The funding is part of Koda's oversubscribed series A funding round that closed in October, according to a release.

"UPMC Enterprises’ investment is a meaningful signal, not just to Koda, but to the broader market," Dr. Desh Mohan, chief medical officer and co-founder of Koda Health, said in the news release. "It validates that health systems are ready to invest in infrastructure that makes advance care planning work the way it should: proactively, at scale, and with the human support that these conversations require. Having UPMC Enterprises as a strategic investor puts us in a unique position to prove what's possible."

Koda has raised $14 million to date, according to a representative from the company. Its series A round was led by Evidenced, with participation from Mudita Venture Partners, Techstars and the Texas Medical Center last year. At the time, the company said the funding would allow it to scale operations and expand engineering, clinical strategy and customer success. The company described the round as a "pivotal moment," as it had secured investments from influential leaders in the healthcare and venture capital space.

Koda Health, which was born out of the TMC's Biodesign Fellowship in 2020, saw major growth last year, as well, and now supports more than 1 million patients nationwide through partnerships with Cigna Healthcare, Privia Health, Guidehealth, Sentara, UPMC and Memorial Hermann Health System.

The company integrated its end-of-life care planning platform with Dallas-based Guidehealth in April 2025 and with Epic Systems in July 2025. It also won the 2025 Houston Innovation Award in the Health Tech Business category. Read more here.

New 'living pharmacy' biotech company launches out of Rice venture studio

fighting cancer

Rice University’s biotech venture studio RBL LLC has launched a new “living pharmacy” company, Duracyte, designed to make cancer treatment easier on patients.

Backed by an up to $45 million Advanced Research Projects Agency for Health (ARPA-H) award, Duracyte aims to commercialize implantable biohybrid pharmacy devices that are designed to produce therapeutic proteins inside the human body around the clock, replacing the need for regular injections and infusions for some cancer patients.

The company’s main platform is its Hybrid Advanced Molecular Manufacturing Regulator (HAMMR), a rechargeable, implantable device that can sense biological signals, monitor tumor environments and adjust therapeutic output in real time. HAMMR has wireless communication capabilities, which allow patients and clinicians to remotely monitor results through an app every five minutes and make changes to treatment plans without a hosptial visit. Additionally, the device can generate its own oxygen supply, which is key for the therapeutic cells’ survival.

“Biologic medicines such as monoclonal antibodies, cytokines and metabolic regulators already account for a significant share of modern therapeutics, but the way we deliver them today often requires frequent injections or infusions that can be demanding for patients and lead to inconsistent drug levels,” Daniel Anderson, MIT professor and co-founder of Duracyte, said in a news release. “Our vision is to enable a continuous, stable therapy by producing these medicines directly inside the body, which could improve treatment consistency, reduce side effects and ultimately transform how biologic therapies are delivered across many diseases.”

Duracyte’s first clinical trial is slated to begin by the end of 2026 and will focus on recurrent ovarian cancer. The Phase I study will build upon existing work on encapsulated cytokine pharmacy technology, and the company hopes that within a few years this treatment can reach clinical application.

The development of Duracyte is supported by ARPA-H's Targeted Hybrid Oncotherapeutic Regulation (THOR) project, which supports a multidisciplinary research consortium co-led by Omid Veiseh, a professor of bioengineering at Rice. The consortium also includes others at Rice, The University of Texas MD Anderson Cancer Center, Stanford University, Carnegie Mellon University, Northwestern University and the University of Houston, plus industry collaborators like Chicago-based CellTrans.

“What we are building is the culmination of years of progress in cell engineering, biomaterials and implantable device technology,” Veiseh added in the release. “By combining these advances with real-time sensing and adaptive drug delivery, we are working with the support of RBL to create a true ‘living pharmacy’ that can deliver continuous, precisely controlled biologic therapies and fundamentally change how these treatments reach patients.”

RBL launched in 2024 and is based out of Houston’s Texas Medical Center Helix Park. Duracyte is the third company launched by RBL, including Sentinel BioTherapeutics, a clinical-stage immunotherapy company developing localized cytokine therapies for solid tumors, and SteerBio, a regenerative medicine company targeting lymphedema.

“Duracyte exemplifies the kind of breakthrough that Houston’s ecosystem is built to produce,” Paul Wotton, managing partner of RBL LLC and co-founder of Duracyte, added in the release. “With world-class clinical infrastructure, exceptional engineering talent and initiatives like the Texas Biotech Task Force driving alignment across industry, investment and talent, this region is uniquely positioned to move the most ambitious ideas in medicine from concept to patient, faster than anywhere else.”